News Moderna shows in vivo CAR-T hand in R&D update At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.
News AbbVie's ovarian cancer drug Elahere gets NHS green light AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.
News Data backs GSK's ovarian cancer blockbuster hopes GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.
News Corcept gets FDA OK for first-in-class ovarian cancer drug Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.
Patients New hope for ovarian cancer, with Alexander Schneider Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
